An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy

Liron Caplan, Cory B. Pittman, Angelique L. Zeringue, Jeffrey F. Scherrer, Kent R. Wehmeier, Francesca E. Cunningham, Seth A. Eisen, Jay R. Mcdonald

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

OBJECTIVE: To seek evidence for the association of bisphosphonate use with diffuse musculoskeletal pain (MSKP) in a large national cohort, controlling for conditions associated with MSKP. PATIENTS AND METHODS: This retrospective cohort study enrolled all US veterans aged 65 years or older with a vertebral or hip fracture who were treated for at least 1 year between October 1, 1998, and September 30, 2006 (N=26,545). All International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, demographics, and pharmaceutical data were obtained from national databases. A composite end point, based on ICD-9-CM codes compatible with diffuse MSKP, was constructed. The primary outcome was time until MSKP. We performed regression analysis using the Cox proportional hazards model, controlling for age, sex, race, alcoholism, depression, anxiety, smoking, recent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use, rheumatic disease, and comorbidity score. RESULTS: The univariate regression identified an association of bisphosphonate exposure and MSKP (hazard ratio, 1.22; 95% confidence interval, 1.04-1.44). In the multivariate regression, however, patients prescribed a bisphosphonate were not more likely to be assigned an ICD-9-CM code compatible with diffuse MSKP (hazard ratio, 1.10; 95% confidence interval, 0.93-1.30). Consistent with prior studies, we found that female sex, depression, anxiety, comorbidity score, and the presence of a rheumatic disease were all associated with a greater risk of a diagnosis of diffuse MSKP. There was no demonstrable association with statin exposure. CONCLUSION: Bisphosphonate use was not associated with a statistically higher rate of MSKP in this cohort. Individual patients may rarely report MSKP while taking bisphosphonates; however, for our studied cohort, incident MSKP does not appear to explain bisphosphonate discontinuation rates.

Original languageEnglish
Pages (from-to)341-348
Number of pages8
JournalMayo Clinic Proceedings
Volume85
Issue number4
DOIs
StatePublished - Apr 2010

Keywords

  • HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A
  • HR = hazard ratio
  • ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification
  • MSKP = musculoskeletal pain
  • OR = odds ratio
  • VA = US department of veterans affairs

Fingerprint

Dive into the research topics of 'An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy'. Together they form a unique fingerprint.

Cite this